N-Acetylcysteine and Cognitive Impairment: Adjuvant Treatment Mediated by Oxidative Stress
Keywords:
Mild cognitive impairment; N-acetylcyteine; oxidative stress; glutathioneAbstract
The potential of N-acetylcysteine as an adjuvant therapy in mild cognitive impairment is analyzed, highlighting its role in modulating oxidative stress and restoring glutathione levels. Epidemiological, clinical, and experimental findings suggesting neuroprotective effects and improvements in cognitive function are integrated. However, clinical evidence remains limited, and further prospective studies are required to validate its efficacy.
Downloads
References
1. Alzheimer’s Disease International, Clare, L, Jeon, YH. 2025. World Alzheimer Report 2025: Reimagining life with dementia – the power of rehabilitation. London, England: Alzheimer’s Disease Internationala. [Citado 03 Abril 2026]. Disponible en: https://www.alzint.org/u/World-Alzheimer-Report-2025.pdf
2. Frye R, Berk M, editores. The therapeutic use of N-acetylcysteine (NAC) in medicine. 1a ed. Singapur, Singapur: Springer; 2018. https://link.springer.com/book/10.1007/978-981-10-5311-5
3. Chakraborty S, Shankaranarayana Rao BS, Tripathi SJ. The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders: From modulation of glutamatergic transmission to restoration of synaptic plasticity. Neuropharmacology [Internet]. 2025;278(110527):110527. Disponible en: http://dx.doi.org/10.1016/j.neuropharm.2025.110527
4. Nichols E, Steinmetz J, Vollset S et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 The Lancet Public Health, 2022; 7, e105-e125
5. 2025 Alzheimer’s disease facts and figures. Alzheimer's Dement [Internet]. 2025;21(4). Disponible en: http://dx.doi.org/10.1002/alz.70235
6. Directrices de la OMS para la reducción de los riesgos de deterioro cognitivo y demencia [Internet]. Washington (DC): Organización Panamericana de la Salud; 2020. 1, Introducción. Available from: https://www.ncbi.nlm.nih.gov/books/NBK583455/
7. Mangalagiu A, Petrescu B, Riga S, Vasiliu O. Pharmacological Management of Mild Cognitive Impairment: From Symptomatic Treatment to Disease Modification—A Narrative Review. NeuroSci. 2026; 7(1):2. https://doi.org/10.3390/neurosci7010002
8. Remington R, Bechtel C, Larsen D, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Page R, Morrell C, Shea TB. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. J Alzheimers Dis. 2015;45(2):395-405. doi: 10.3233/JAD-142499. PMID: 25589719.
9. Rapado-Castro M, Dodd S, Bush AI, Malhi GS, Skvarc DR, On ZX, et al. Efectos cognitivos de la N-acetilcisteína como tratamiento coadyuvante en la psicosis. Psychological Medicine. 2017;47(5):866–76. doi:10.1017/S0033291716002932
10. Nitrini R, Bottino CM, Albala C, Custodio Capuñay NS, Ketzoian C, Llibre Rodriguez JJ, Maestre GE, Ramos-Cerqueira AT, Caramelli P. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. Int Psychogeriatr. 2009 Aug;21(4):622-30. doi: 10.1017/S1041610209009430.
11. da Costa M, Bernardi J, Costa L, Fiuza T, Brandão R, Ribeiro MF, et al. N-acetylcysteine treatment attenuates the cognitive impairment and synaptic plasticity loss induced by streptozotocin. Chem Biol Interact [Internet]. 2017;272:37–46. Disponible en: http://dx.doi.org/10.1016/j.cbi.2017.05.008
12. Pan, X., Su, Z., Huang, Z. et al. N-acetylcysteine (NAC) ameliorates ethanol-induced oxidative stress, neuroinflammation, and cognitive dysfunction in APP/PS1 mouse model. Transl Psychiatry 15, 435 (2025). https://doi.org/10.1038/s41398-025-03496-z
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Piero Renato Barrios Aparicio, Healey Sacha Barrios, Vela Ruiz José Manuel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
